EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Efficacy and Mechanism of Combining Radiotherapy and Immunotherapy in Stage IV Non-Small Cell Lung Cancer

Mingyue Wang, Shuo Li, Runyu Li, Fangling Ning, Lijun Tian

Current Treatment Options in Oncology · 2024-12 · 25 (12) · 1605-1614

DOI: 10.1007/s11864-024-01260-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Current Treatment Options in Oncology, online erschienen am 03.12.2024. Verfasst von Mingyue Wang und 4 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Oncology, Binzhou Medical University Hospital, Binzhou City, Shandong Province, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Staging, Immunotherapy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Science and Technology Innovation Medical Development Foundation, ShanDong Provincial Medical Association.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OPINION STATEMENT: Lung cancer is the leading cause of cancer-related deaths worldwide, with about 85% of patients being diagnosed as non-small cell lung cancer (NSCLC); and most presenting with stage IV disease initially. With the continuous advancement of treatment strategies of oncology, immunotherapy with/without chemo-immunotherapy has become the first-line treatment for patients with stage IV NSCLC. However, a proportion of patients still develop resistance to the treatment regimen and experience local progression, and primary lung lesion progression is the main progression pattern of stage IV NSCLC. Preclinical and clinical studies have demonstrated the potential of radiotherapy in anti-tumor treatment and suggest that administering local radiotherapy prior to cancer progression can prolong survival. Therefore, we consider whether adding local radiotherapy before the progression of a pulmonary lesion in stage IV NSCLC patients receiving chemo-immunotherapy would be beneficial. The present review aims to explore the efficacy and safety of combining radiotherapy with immunotherapy in the treatment of stage IV NSCLC, delving into the intricacies of their underlying mechanism.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsNeoplasm StagingImmunotherapyHumansCombined Modality TherapyTreatment OutcomeDisease ManagementChemoradiotherapy

Stichwörter der Autor:innen

Combination treatmentImmunotherapyRadiotherapyStage IV NSCLC

Autor:innen und Institutionen

  • The Department of Oncology, Binzhou Medical University Hospital, Binzhou City, Shandong Province, China.
  • The Department of Oncology, Binzhou Medical University Hospital, Binzhou City, Shandong Province, China. byfyzlt@bzmc.edu.cn.

Förderung

  • Beijing Science and Technology Innovation Medical Development Foundation
  • ShanDong Provincial Medical Association

Zitieren

APA

Wang, M., Li, S., Li, R., Ning, F., & Tian, L. (2024). Efficacy and Mechanism of Combining Radiotherapy and Immunotherapy in Stage IV Non-Small Cell Lung Cancer. Current Treatment Options in Oncology, 25(12), 1605-1614. https://doi.org/10.1007/s11864-024-01260-x

Vancouver

Wang M, Li S, Li R, Ning F, Tian L. Efficacy and Mechanism of Combining Radiotherapy and Immunotherapy in Stage IV Non-Small Cell Lung Cancer. Current Treatment Options in Oncology. 2024;25(12):1605-1614. doi:10.1007/s11864-024-01260-x

BibTeX
@article{Wang2024,
  author = {Wang, Mingyue and Li, Shuo and Li, Runyu and Ning, Fangling and Tian, Lijun},
  title = {Efficacy and Mechanism of Combining Radiotherapy and Immunotherapy in Stage IV Non-Small Cell Lung Cancer},
  journal = {Current Treatment Options in Oncology},
  year = {2024},
  volume = {25},
  number = {12},
  pages = {1605--1614},
  doi = {10.1007/s11864-024-01260-x}
}
Kostenlos starten →